SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), announced today that the U.S. Food and Drug Administration (FDA) has approved new software for ...

This latest software enhancement to DexCom G4 Platinum will make the performance level of blood glucose monitoring comparable to finger stick meters, the traditional standard-of-care for the same.

New Dexcom software achieves critical milestone in measured accuracy for continuous glucose monitoring SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., (NASDAQ:DXCM), a leader in continuous glucose ...

DexCom, Inc. ( DXCM) recently revealed the U.S. Food and Drug Administration (FDA) approval for a new algorithm designed for its G4 PLATINUM Continuous Glucose Monitoring (CGM) system. Following the ...

Dexcom announced recently that the U.S. Food and Drug Administration (FDA) has approved new software for the Dexcom G4 PLATINUM CGM. The new Software 505 features the same advanced algorithm as used ...

[Image from Dexcom] The CEO of Dexcom (Nasdaq:DXCM) said today that the company’s regulatory path for the next-generation G7 has been slightly delayed. Speaking on the continuous glucose monitor (CGM) ...

DexCom's not just a diabetes company anymore. They're at the forefront of wearable health tech, blurring the lines between medicine and lifestyle. DexCom might not be the flashiest stock, but their ...

Dexcom, the company behind one of the leading continuous glucose monitor solutions for diabetes patients, has announced today that their “Follow” mobile app—which has long been available on iOS—is now ...

Dexcom’s stock fell Friday morning following the announcement that clearance for the much-anticipated G7 continuous glucose monitoring system will be delayed until late 2022. CEO Kevin Sayer said ...

(Corrects to identify the issue is with the Dexcom Follow monitoring service, not the monitor itself) NEW YORK, Dec 1 (Reuters) - Dexcom Inc, which makes continuous glucose monitoring systems that can ...